These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30989998)

  • 21. [Hyperhomocysteinemia--a predictor of inflammatory changes in the liver].
    Zviagintseva TD; Hlushchenko SV
    Lik Sprava; 2014 Nov; (11):154-5. PubMed ID: 25528857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in patients with HIV.
    Verna EC
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):211-223. PubMed ID: 28404136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic Fatty liver disease.
    Mansoor S; Collyer E; Alkhouri N
    Curr Gastroenterol Rep; 2015 Jun; 17(6):23. PubMed ID: 26031832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated liver stiffness measurement compared with paired liver biopsy in patients with non-alcoholic fatty liver disease.
    Kamarajah SK; Chan WK; Nik Mustapha NR; Mahadeva S
    Hepatol Int; 2018 Jan; 12(1):44-55. PubMed ID: 29372507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):123-131. PubMed ID: 27599824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum immunoreactive collagen IV detected by monoclonal antibodies as a marker of severe fibrosis in patients with non-alcoholic fatty liver disease.
    Aida Y; Abe H; Tomita Y; Nagano T; Seki N; Sugita T; Itagaki M; Ishiguro H; Sutoh S; Aizawa Y
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):61-8. PubMed ID: 25822435
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The Progression of Liver Fibrosis in Non-alcoholic Fatty Liver Disease].
    Kim MY
    Korean J Gastroenterol; 2017 Jun; 69(6):341-347. PubMed ID: 28637102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016.
    Kaswala DH; Lai M; Afdhal NH
    Dig Dis Sci; 2016 May; 61(5):1356-64. PubMed ID: 27017224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?
    Hashimoto E; Farrell GC
    J Gastroenterol Hepatol; 2009 Apr; 24(4):501-3. PubMed ID: 19368628
    [No Abstract]   [Full Text] [Related]  

  • 30. AST to Platelet Ratio Index and fibrosis 4 calculator scores for non-invasive assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease.
    Peleg N; Issachar A; Sneh-Arbib O; Shlomai A
    Dig Liver Dis; 2017 Oct; 49(10):1133-1138. PubMed ID: 28572039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin Resistance but Not Visceral Adiposity Index Is Associated with Liver Fibrosis in Nondiabetic Subjects with Nonalcoholic Fatty Liver Disease.
    Ercin CN; Dogru T; Genc H; Celebi G; Aslan F; Gurel H; Kara M; Sertoglu E; Tapan S; Bagci S; Rizzo M; Sonmez A
    Metab Syndr Relat Disord; 2015 Sep; 13(7):319-25. PubMed ID: 26011302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese.
    Ooi GJ; Mgaieth S; Eslick GD; Burton PR; Kemp WW; Roberts SK; Brown WA
    Obes Rev; 2018 Feb; 19(2):281-294. PubMed ID: 29119725
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interfering parameters in nonalcoholic fatty liver disease fibrosis score.
    Sertoglu E; Kayadibi H; Uyanik M
    Liver Int; 2015 Jan; 35(1):285. PubMed ID: 25102955
    [No Abstract]   [Full Text] [Related]  

  • 34. Prevalence and Predictors of Significant Fibrosis Among Subjects with Transient Elastography-Defined Nonalcoholic Fatty Liver Disease.
    Lee HW; Kim BK; Kim SU; Park JY; Kim DY; Ahn SH; Kim KJ; Han KH
    Dig Dis Sci; 2017 Aug; 62(8):2150-2158. PubMed ID: 28523578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease.
    Calès P; Boursier J; Chaigneau J; Lainé F; Sandrini J; Michalak S; Hubert I; Dib N; Oberti F; Bertrais S; Hunault G; Cavaro-Ménard C; Gallois Y; Deugnier Y; Rousselet MC
    Liver Int; 2010 Oct; 30(9):1346-54. PubMed ID: 20666992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
    Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
    Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review.
    Peng Y; Li Y; He Y; Wei Q; Xie Q; Zhang L; Xia Y; Zhou X; Zhang L; Feng X; Chen K; Chen S; Chen W; Long Q; Chai J
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):503-513. PubMed ID: 29629626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical interpretation of Fibroscan® results: a real challenge.
    Boursier J; Calès P
    Liver Int; 2010 Nov; 30(10):1400-2. PubMed ID: 20849438
    [No Abstract]   [Full Text] [Related]  

  • 39. A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects.
    Giraudi PJ; Gambaro SE; Ornelas Arroyo S; Chackelevicius CM; Giuricin M; Silvestri M; Macor D; Crocé LS; Bonazza D; Soardo G; de Manzini N; Zanconati F; Tiribelli C; Palmisano S; Rosso N
    Liver Int; 2018 Jan; 38(1):155-163. PubMed ID: 28650518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease.
    Petta S; Ciminnisi S; Di Marco V; Cabibi D; Cammà C; Licata A; Marchesini G; Craxì A
    Aliment Pharmacol Ther; 2017 Feb; 45(4):510-518. PubMed ID: 28028821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.